Credit Agricole S A Purchases 12,929 Shares of TransMedics Group, Inc. $TMDX

Key Points

• Credit Agricole S A significantly increased its stake in TransMedics Group by 116%, acquiring 12,929 shares and bringing its total ownership to 24,079 shares valued at approximately $1.62 million.
• TransMedics Group recently reported $0.92 EPS for the quarter, which surpassed analysts' expectations, and its revenue grew 37.7% year-over-year.
• Institutional investors hold a significant majority of TransMedics Group's shares, with 99.67% ownership, indicating strong institutional interest in the company.

Credit Agricole S A increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 116.0% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,079 shares of the company's stock after buying an additional 12,929 shares during the period. Credit Agricole S A owned 0.07% of TransMedics Group worth $1,620,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of TMDX. Raymond James Financial Inc. bought a new position in TransMedics Group during the fourth quarter worth $3,845,000. Dimensional Fund Advisors LP raised its stake in TransMedics Group by 1,565.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock worth $16,820,000 after buying an additional 253,624 shares during the last quarter. MetLife Investment Management LLC grew its holdings in TransMedics Group by 6.0% in the fourth quarter. MetLife Investment Management LLC now owns 19,640 shares of the company's stock worth $1,225,000 after purchasing an additional 1,116 shares during the period. Teachers Retirement System of The State of Kentucky grew its holdings in TransMedics Group by 296.8% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 11,070 shares of the company's stock worth $690,000 after purchasing an additional 8,280 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in TransMedics Group by 1,602.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,359 shares of the company's stock worth $272,000 after purchasing an additional 4,103 shares during the period. Institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Up 0.9%

Shares of NASDAQ TMDX opened at $119.85 on Monday. The stock has a market capitalization of $4.09 billion, a P/E ratio of 62.10 and a beta of 2.09. The company has a 50-day moving average price of $121.65 and a 200-day moving average price of $101.70. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business's revenue was up 37.7% on a year-over-year basis. During the same period last year, the company earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, Director Edward M. Basile sold 5,000 shares of TransMedics Group stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the transaction, the director directly owned 2,866 shares in the company, valued at $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider directly owned 13,955 shares in the company, valued at $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on TMDX. Oppenheimer raised their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Piper Sandler restated an "overweight" rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Morgan Stanley raised their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Finally, Wall Street Zen upgraded shares of TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of "Moderate Buy" and a consensus target price of $123.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.